{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:08:19Z","timestamp":1793678899275,"version":"4.5.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Beta-blockers, originally developed for cardiovascular conditions, have been explored for their potential role in cancer treatment. Propranolol, a non-selective beta-blocker, has shown promise in inhibiting stress-induced signalling pathways associated with cancer progression. This systematic review aims to assess the evidence for the repurposing of propranolol as a treatment for various cancers, particularly breast cancer to answer the research question:\n                      <jats:italic>Does propranolol improve cancer outcomes, including survival and recurrence?<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of MEDLINE, EMBASE, Global Health, Web of Science, and the Cochrane Library, including studies up to July 2024. Randomised Controlled Trials (RCTs), systematic reviews, and meta-analyses were included if they assessed the effects of propranolol on cancer outcomes such as mortality, survival, recurrence, or biomarkers of tumour regression. A narrative synthesis was performed to summarise the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one studies were included, consisting of 7 RCTs, 4 systematic reviews and 20 meta-analyses. The evidence suggests that propranolol may improve cancer outcomes, especially when administered perioperatively, by reducing recurrence risk. However, the results remain inconclusive regarding its use in combination with chemotherapy or radiotherapy, as studies showed mixed results. The timing of propranolol administration, alongside its combination with other cancer therapies, appears to be a key factor in its effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Propranolol has potential as an adjunctive therapy in cancer treatment, particularly in reducing recurrence risk during the perioperative period. However, further clinical trials are needed to better define its role in cancer therapy, particularly regarding optimal treatment regimens and patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06262-2","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T19:43:08Z","timestamp":1752349388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers"],"prefix":"10.1007","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-9703","authenticated-orcid":false,"given":"Jessica","family":"O\u2019Logbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-1997","authenticated-orcid":false,"given":"Ludovica","family":"Tarantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-312X","authenticated-orcid":false,"given":"Norman R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreeya","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-5336","authenticated-orcid":false,"given":"Aamir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2325-0849","authenticated-orcid":false,"given":"Elizabeth A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"3","key":"6262_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/J.YGYNO.2016.09.019","volume":"143","author":"A Al-Niaimi","year":"2016","unstructured":"Al-Niaimi A, Dickson EL, Albertin C, Karnowski J, Niemi C, Spencer R, Shahzad MMK, Uppal S, Saha S, Rice L, Nally AM (2016) The impact of perioperative \u03b2 blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Gynecol Oncol 143(3):521\u2013525. https:\/\/doi.org\/10.1016\/J.YGYNO.2016.09.019","journal-title":"Gynecol Oncol"},{"issue":"24","key":"6262_CR2","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1113\/JP278661","volume":"597","author":"J Ashmore","year":"2019","unstructured":"Ashmore J, Olsen H, S\u00f8rensen N, Thrasivoulou C, Ahmed A (2019) Wnts control membrane potential in mammalian cancer cells. J Physiol 597(24):5899\u20135914. https:\/\/doi.org\/10.1113\/JP278661","journal-title":"J Physiol"},{"issue":"22","key":"6262_CR3","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.3390\/IJMS21228760","volume":"21","author":"M Barathova","year":"2020","unstructured":"Barathova M, Grossmannova K, Belvoncikova P, Kubasova V, Simko V, Skubla R, Csaderova L, Pastorek J (2020) Impairment of hypoxia-induced CA IX by beta-blocker propranolol\u2014impact on progression and metastatic potential of colorectal cancer cells. Int J Mol Sci 21(22):8760. https:\/\/doi.org\/10.3390\/IJMS21228760","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6262_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/35036035","volume":"1","author":"MJ Berridge","year":"2000","unstructured":"Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1(1):11\u201321. https:\/\/doi.org\/10.1038\/35036035","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"6262_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/S10549-013-2654-3","volume":"140","author":"E Botteri","year":"2013","unstructured":"Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, Zanelotti A, Adamoli L, Colleoni M, Viale G, Goldhirsch A, Gandini S (2013) Therapeutic effect of \u03b2-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 140(3):567\u2013575. https:\/\/doi.org\/10.1007\/S10549-013-2654-3","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"6262_CR7","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1158\/0008-5472.CAN-17-0546","volume":"77","author":"MJ Bucsek","year":"2017","unstructured":"Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JWL, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA (2017) \u03b2-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Can Res 77(20):5639\u20135651. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0546","journal-title":"Can Res"},{"key":"6262_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100066","author":"R Caparica","year":"2021","unstructured":"Caparica R, Bruzzone M, Agostinetto E, De Angelis C, F\u00eade \u00c2, Ceppi M, de Azambuja E (2021) Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100066","journal-title":"ESMO Open"},{"key":"6262_CR9","doi-asserted-by":"publisher","unstructured":"Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PAJ, O\u2019Rorke M, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MPP, Gavin A, Friis S, Sharp L, Bennett K (2016) Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Res: BCR 18(1):119. https:\/\/doi.org\/10.1186\/s13058-016-0782-5","DOI":"10.1186\/s13058-016-0782-5"},{"issue":"1","key":"6262_CR10","doi-asserted-by":"publisher","first-page":"2284486","DOI":"10.1080\/2162402X.2023.2284486","volume":"12","author":"K Carnet Le Provost","year":"2023","unstructured":"Carnet Le Provost K, Kepp O, Kroemer G, Bezu L (2023) Trial watch: beta-blockers in cancer therapy. Oncoimmunology 12(1):2284486. https:\/\/doi.org\/10.1080\/2162402X.2023.2284486","journal-title":"Oncoimmunology"},{"issue":"13","key":"6262_CR11","doi-asserted-by":"publisher","DOI":"10.1096\/FJ.202400725RR","volume":"38","author":"S Cavalu","year":"2024","unstructured":"Cavalu S, Saber S, Amer AE, Hamad RS, Abdel-Reheim MA, Elmorsy EA, Abdelhamid AM (2024) The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders. FASEB J 38(13):e23813. https:\/\/doi.org\/10.1096\/FJ.202400725RR","journal-title":"FASEB J"},{"issue":"3","key":"6262_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10238-022-00842-z","volume":"23","author":"H Chang","year":"2023","unstructured":"Chang H, Lee SH (2023) Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis. Clin Exp Med 23(3):853\u2013858. https:\/\/doi.org\/10.1007\/s10238-022-00842-z","journal-title":"Clin Exp Med"},{"issue":"6","key":"6262_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.clbc.2015.07.001","volume":"15","author":"WK Childers","year":"2015","unstructured":"Childers WK, Hollenbeak CS, Cheriyath P (2015) \u03b2-Blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer 15(6):426\u2013431. https:\/\/doi.org\/10.1016\/j.clbc.2015.07.001","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"6262_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","volume":"140","author":"CH Choi","year":"2014","unstructured":"Choi CH, Song T, Kim TH, Choi JK, Park JY, Yoon A, Lee YY, Kim TJ, Bae DS, Lee JW, Kim BG (2014) Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol 140(7):1179\u20131188. https:\/\/doi.org\/10.1007\/s00432-014-1658-7","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"6262_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/CEJ.0000000000000544","volume":"29","author":"M Coelho","year":"2020","unstructured":"Coelho M, Squizzato A, Cassina N, Marino F, Ribeiro LV, Cosentino M (2020) Effect of beta-blockers on survival of lung cancer patients: a systematic review and meta-analysis. Eur J Cancer Prevent: off J Eur Cancer Prevent Org (ECP) 29(4):306\u2013314. https:\/\/doi.org\/10.1097\/CEJ.0000000000000544","journal-title":"Eur J Cancer Prevent: off J Eur Cancer Prevent Org (ECP)"},{"issue":"5","key":"6262_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2011","unstructured":"Cole SW, Sood AK (2011) Molecular Pathways: Beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0641","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6262_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/NRCLINONC.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7(4):209\u2013219. https:\/\/doi.org\/10.1038\/NRCLINONC.2010.21","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6262_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/VCO.12560","volume":"18","author":"MM Duckett","year":"2020","unstructured":"Duckett MM, Phung SK, Nguyen L, Khammanivong A, Dickerson E, Dusenbery K, Lawrence J (2020) The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells. Veterinary Comparative Oncol 18(1):128\u2013140. https:\/\/doi.org\/10.1111\/VCO.12560","journal-title":"Veterinary Comparative Oncol"},{"issue":"19","key":"6262_CR19","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.2174\/138161212800626210","volume":"18","author":"A Fasolo","year":"2012","unstructured":"Fasolo A, Sessa C (2012) Targeting mTOR pathways in human malignancies. Curr Pharm des 18(19):2766\u20132777. https:\/\/doi.org\/10.2174\/138161212800626210","journal-title":"Curr Pharm des"},{"issue":"6","key":"6262_CR20","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.3390\/molecules18066584","volume":"8","author":"YC Guo","year":"2013","unstructured":"Guo YC, Chang CM, Hsu WL, Chiu SJ, Tsai YT, Chou YH, Hou MF, Wang JY, Lee MH, Tsai KL, Chang WC (2013) Indomethacin inhibits cancer cell migration via attenuation of cellular calcium mobilization. Molecules 8(6):6584\u20136596","journal-title":"Molecules"},{"issue":"18","key":"6262_CR21","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-15-0260","volume":"21","author":"MP Gustafson","year":"2015","unstructured":"Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR, Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB (2015) Intratumoral CD14+ cells and circulating CD14+HLA-DRlo\/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. Clin Cancer Res: off J Am Assoc Cancer Res 21(18):4224\u20134233. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0260","journal-title":"Clin Cancer Res: off J Am Assoc Cancer Res"},{"issue":"17","key":"6262_CR22","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1002\/cncr.32950","volume":"126","author":"R Haider","year":"2020","unstructured":"Haider R, Ricon-Becker I, Radin A, Gutman M, Cole SW, Zmora O, Ben-Eliyahu S, Haldar R, Ricon-Becker I, Radin A, Gutman M, Cole SW, Zmora O, Ben-Eliyahu S (2020) Perioperative COX2 and \u03b2-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: a randomized controlled trial. Cancer 126(17):3991\u20134001. https:\/\/doi.org\/10.1002\/cncr.32950","journal-title":"Cancer"},{"key":"6262_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbi.2018.05.014","volume":"73","author":"R Haldar","year":"2018","unstructured":"Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S (2018) Perioperative inhibition of beta-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain, Behavior, Immun 73:294\u2013309","journal-title":"Brain, Behavior, Immun"},{"issue":"3","key":"6262_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ygyno.2013.03.007","volume":"129","author":"F Heitz","year":"2013","unstructured":"Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J (2013) Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group. NCIC-CTG EORTC-GCG. Gynecologic Oncol 129(3):463\u2013466","journal-title":"NCIC-CTG EORTC-GCG. Gynecologic Oncol"},{"key":"6262_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.D5928","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovi\u0107 J, Schulz KF, Weeks L, Sterne JAC (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/BMJ.D5928","journal-title":"BMJ"},{"issue":"4","key":"6262_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/NRCLINONC.2017.194","volume":"15","author":"JG Hiller","year":"2018","unstructured":"Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK (2018) Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol 15(4):205\u2013218. https:\/\/doi.org\/10.1038\/NRCLINONC.2017.194","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"6262_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1158\/1078-0432.CCR-19-2641","volume":"26","author":"JG Hiller","year":"2020","unstructured":"Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, Henderson MA, Nightingale SS, Ho KM, Myles PS et al (2020) Preoperative \u03b2-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial. Clin Cancer Res 26(8):1803\u20131811","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6262_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/J.BJPS.2010.07.009","volume":"64","author":"WJM Holmes","year":"2011","unstructured":"Holmes WJM, Mishra A, Gorst C, Liew SH (2011) Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plastic, Reconstructive Aesth Surg: JPRAS 64(4):445\u2013451. https:\/\/doi.org\/10.1016\/J.BJPS.2010.07.009","journal-title":"J Plastic, Reconstructive Aesth Surg: JPRAS"},{"issue":"1","key":"6262_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4161\/CBT.3.1.561","volume":"3","author":"LR Howe","year":"2004","unstructured":"Howe LR, Brown AMC (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3(1):36\u201341. https:\/\/doi.org\/10.4161\/CBT.3.1.561","journal-title":"Cancer Biol Ther"},{"key":"6262_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040406","author":"FJ Huettner","year":"2020","unstructured":"Huettner FJ, Rooman I, Bouche G, Knebel P, Huesing J, Mihaljevic AL, Hackert T, Strobel O, Buechler MW, Diener MK (2020) Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2020-040406","journal-title":"BMJ Open"},{"issue":"18","key":"6262_CR31","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.2174\/15680266113136660163","volume":"13","author":"N Issa","year":"2013","unstructured":"Issa N, Byers S, Dakshanamurthy S (2013) Drug repurposing: translational pharmacology, chemistry, computers and the clinic. Curr Top Med Chem 13(18):2328\u20132336. https:\/\/doi.org\/10.2174\/15680266113136660163","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"6262_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000455143","volume":"92","author":"HY Kim","year":"2017","unstructured":"Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K (2017) Is beta-blocker use beneficial in breast cancer? Meta-Anal Oncol 92(5):264\u2013268. https:\/\/doi.org\/10.1159\/000455143","journal-title":"Meta-Anal Oncol"},{"issue":"1","key":"6262_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1078-0432.CCR-15-1344","volume":"22","author":"JM Knight","year":"2015","unstructured":"Knight JM, Rizzo JD, Logan BR, Wang T, Arevalo JMG, Ma J, Cole SW (2015) Low socioeconomic status, adverse gene expression profiles, and clinical outcomes in hematopoietic stem cell transplant recipients. Clin Cancer Res: off J Am Ass Cancer Res 22(1):69. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1344","journal-title":"Clin Cancer Res: off J Am Ass Cancer Res"},{"issue":"3","key":"6262_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/bloodadvances.2019000765","volume":"4","author":"JM Knight","year":"2020","unstructured":"Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D\u2019Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW (2020) Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Advnces 4(3):467\u2013476","journal-title":"Blood Advnces"},{"key":"6262_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1405205","author":"KM Kokolus","year":"2017","unstructured":"Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Drabick JJ, Schell TD (2017) Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2017.1405205","journal-title":"Oncoimmunology"},{"issue":"8","key":"6262_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Voisard J-J (2015) A randomized, controlled trial of oral propranolol in infantile hemangioma. New England J Med 372(8):735\u2013746","journal-title":"New England J Med"},{"issue":"2","key":"6262_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245773","volume":"16","author":"Z Lei","year":"2021","unstructured":"Lei Z, Yang W, Zuo Y (2021) Beta-blocker and survival in patients with lung cancer: a meta-analysis. PLoS ONE 16(2):e0245773. https:\/\/doi.org\/10.1371\/journal.pone.0245773","journal-title":"PLoS ONE"},{"key":"6262_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/964842","volume":"2015","author":"J Li","year":"2015","unstructured":"Li J, Ji L, Chen J, Zhang W, Ye Z (2015) Wnt\/\u03b2-Catenin signaling pathway in skin carcinogenesis and therapy. Biomed Res Int 2015:964842. https:\/\/doi.org\/10.1155\/2015\/964842","journal-title":"Biomed Res Int"},{"key":"6262_CR39","doi-asserted-by":"publisher","unstructured":"Li C, Li T, Tang R, Yuan S, Zhang W (2020) \u03b2-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis.\u00a0Biosci Rep,\u00a040(6), BSR20200721. https:\/\/doi.org\/10.1042\/BSR20200721","DOI":"10.1042\/BSR20200721"},{"key":"6262_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2147\/DDDT.S160865","volume":"12","author":"X Liao","year":"2018","unstructured":"Liao X, Chaudhary P, Qiu G, Che X, Fan L (2018) The role of propranolol as a radiosensitizer in gastric cancer treatment. Drug des Dev Ther 12:639\u2013645. https:\/\/doi.org\/10.2147\/DDDT.S160865","journal-title":"Drug des Dev Ther"},{"issue":"6","key":"6262_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-022-01891-7","volume":"127","author":"LL L\u00f8fling","year":"2022","unstructured":"L\u00f8fling LL, St\u00f8er NC, Sloan EK, Chang A, Gandini S, Ursin G, Botteri E (2022) \u03b2-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. Br J Cancer 127(6):1086\u20131096. https:\/\/doi.org\/10.1038\/s41416-022-01891-7","journal-title":"Br J Cancer"},{"key":"6262_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1146\/ANNUREV.CELLBIO.20.010403.113126","volume":"20","author":"CY Logan","year":"2004","unstructured":"Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781\u2013810. https:\/\/doi.org\/10.1146\/ANNUREV.CELLBIO.20.010403.113126","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"6262_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ygyno.2020.03.028","volume":"157","author":"A Majidi","year":"2020","unstructured":"Majidi A, Na R, Dixon-Suen S, Jordan SJ, Webb PM (2020) Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol 157(3):678\u2013685","journal-title":"Gynecol Oncol"},{"issue":"12","key":"6262_CR44","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/J.JPEDSURG.2013.08.020","volume":"48","author":"MA Malik","year":"2013","unstructured":"Malik MA, Menon P, Rao KLN, Samujh R (2013) Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg 48(12):2453\u20132459. https:\/\/doi.org\/10.1016\/J.JPEDSURG.2013.08.020","journal-title":"J Pediatr Surg"},{"issue":"19","key":"6262_CR45","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645. https:\/\/doi.org\/10.1200\/JCO.2010.33.4441","journal-title":"J Clin Oncol"},{"key":"6262_CR46","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3389\/fonc.2020.01130","volume":"10","author":"ND Modi","year":"2020","unstructured":"Modi ND, Tan JQE, Rowland A, Koczwara B, Kichenadasse G, McKinnon RA, Wiese MD, Sorich MJ, Hopkins AM (2020) The Influence of pre-existing beta-blockers use on survival outcomes in HER2 positive advanced breast cancer: pooled analysis of clinical trial data. Front Oncol 10:1130. https:\/\/doi.org\/10.3389\/fonc.2020.01130","journal-title":"Front Oncol"},{"issue":"4","key":"6262_CR47","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.18632\/oncotarget.14119","volume":"8","author":"A Montoya","year":"2017","unstructured":"Montoya A, Amaya CN, Belmont A, Diab N, Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S, Khammanivong A, Liss D, Baca ST, Aguilera RJ, Dickerson EB, Torabi A, Dwivedi AK, Abbas A, Chambers K, Nahleh Z (2017) Use of non-selective \u03b2-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget 8(4):6446\u20136460","journal-title":"Oncotarget"},{"issue":"3","key":"6262_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bj.2019.02.003","volume":"42","author":"A Montoya","year":"2019","unstructured":"Montoya A, Varela-Ramirez A, Dickerson E, Pasquier E, Torabi A, Aguilera R, Nahleh Z, Bryan B (2019) The beta-adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. Biomedical J 42(3):155\u2013165. https:\/\/doi.org\/10.1016\/j.bj.2019.02.003","journal-title":"Biomedical J"},{"key":"6262_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/BMJ.N71","journal-title":"BMJ"},{"key":"6262_CR50","doi-asserted-by":"publisher","DOI":"10.3332\/ECANCER.2018.ED82","author":"P Pantziarka","year":"2018","unstructured":"Pantziarka P, Bryan BA, Crispino S, Dickerson EB (2018) Propranolol and breast cancer\u2014a work in progress. Ecancermedicalscience. https:\/\/doi.org\/10.3332\/ECANCER.2018.ED82","journal-title":"Ecancermedicalscience"},{"issue":"10","key":"6262_CR51","doi-asserted-by":"publisher","first-page":"797","DOI":"10.18632\/oncotarget.343","volume":"2","author":"E Pasquier","year":"2011","unstructured":"Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, Andr\u00e9 N (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2(10):797\u2013809","journal-title":"Oncotarget"},{"key":"6262_CR52","doi-asserted-by":"crossref","unstructured":"Peixoto R, Pereira M. de L, Oliveira M (2020) Beta-blockers and cancer: where are we? Pharmaceuticals, 13(6), 105","DOI":"10.3390\/ph13060105"},{"issue":"2","key":"6262_CR53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1124\/JPET.116.236695\/-\/DC1","volume":"360","author":"T Petrou","year":"2017","unstructured":"Petrou T, Olsen HL, Thrasivoulou C, Masters JR, Ashmore JF, Ahmed A (2017) Intracellular calcium mobilization in response to ion channel regulators via a calcium-induced calcium release mechanism. J Pharmacol Exp Ther 360(2):378\u2013387. https:\/\/doi.org\/10.1124\/JPET.116.236695\/-\/DC1","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"6262_CR54","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/oncotarget.197","volume":"1","author":"DG Powe","year":"2010","unstructured":"Powe DG, Voss MJ, Z\u00e4nker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628","journal-title":"Oncotarget"},{"issue":"1","key":"6262_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ijc.30062","volume":"139","author":"S Raimondi","year":"2016","unstructured":"Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, Gandini S (2016) Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. Int J Cancer 139(1):212\u2013219","journal-title":"Int J Cancer"},{"issue":"1","key":"6262_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1124\/JPET.118.254375","volume":"369","author":"M Reyes-Corral","year":"2019","unstructured":"Reyes-Corral M, S\u00f8rensen NM, Thrasivoulou C, Dasgupta P, Ashmore JF, Ahmed A (2019) Differential free intracellular calcium release by class II antiarrhythmics in cancer cell lsines. J Pharmacol Exp Ther 369(1):152\u2013162. https:\/\/doi.org\/10.1124\/JPET.118.254375","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"6262_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T (2020) Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol 13(6):100773. https:\/\/doi.org\/10.1016\/J.TRANON.2020.100773","journal-title":"Transl Oncol"},{"issue":"3","key":"6262_CR58","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ejso.2022.10.013","volume":"49","author":"I Ricon-Becker","year":"2023","unstructured":"Ricon-Becker I, Haldar R, Shabat Simon M, Gutman M, Cole SW, Ben-Eliyahu S, Zmora O (2023) Effect of perioperative COX-2 and beta-adrenergic inhibition on 5-year disease-free-survival in colorectal cancer: a pilot randomized controlled Colorectal Metastasis PreventIon Trial (COMPIT). Eur J Surg Oncol 49(3):655\u2013661. https:\/\/doi.org\/10.1016\/j.ejso.2022.10.013","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"6262_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/S11888-017-0354-9","volume":"13","author":"EM Schatoff","year":"2017","unstructured":"Schatoff EM, Leach BI, Dow LE (2017) Wnt signaling and colorectal cancer. Current Colorectal Cancer Rep 13(2):101. https:\/\/doi.org\/10.1007\/S11888-017-0354-9","journal-title":"Current Colorectal Cancer Rep"},{"key":"6262_CR60","doi-asserted-by":"publisher","unstructured":"Scott OW, TinTin S, Cavadino A, Elwood JM (2024) Beta-blocker use and breast cancer outcomes: a meta-analysis. Breast Cancer Res Treat, 206(3), 443\u2013463. https:\/\/doi.org\/10.1007\/s10549-024-07263-4 PT - Review","DOI":"10.1007\/s10549-024-07263-4"},{"issue":"16","key":"6262_CR61","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","volume":"23","author":"L Shaashua","year":"2017","unstructured":"Shaashua L, Shabat-Simon M, Haldar R, Matzner P, Zmora O, Shabtai M, Sharon E, Allweis T, Barshack I, Hayman L, Arevalo J, Ma J, Horowitz M, Cole S, Ben-Eliyahu S (2017) Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a Phase-II randomized trial. Clin Cancer Res: off J Am Ass Cancer Res 23(16):4651\u20134661","journal-title":"Clin Cancer Res: off J Am Ass Cancer Res"},{"issue":"7","key":"6262_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/MPH.0B013E3182A11658","volume":"35","author":"V Sondhi","year":"2013","unstructured":"Sondhi V, Patnaik SK (2013) Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. J Pediatr Hematol Oncol 35(7):493\u2013499. https:\/\/doi.org\/10.1097\/MPH.0B013E3182A11658","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"6262_CR63","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/annonc\/mdx264","volume":"28","author":"G Spera","year":"2017","unstructured":"Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, Mackey JR (2017) Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE\/TRIO-012 study. Ann Oncology: off J Eur Soc Med Oncol 28(8):1836\u20131841","journal-title":"Ann Oncology: off J Eur Soc Med Oncol"},{"issue":"6","key":"6262_CR64","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4149\/neo_2019_190110N34","volume":"66","author":"A Spini","year":"2019","unstructured":"Spini A, Roberto G, Gini R, Bartolini C, Bazzani L, Donnini S, Crispino S, Ziche M (2019) Evidence of beta-blockers drug repurposing for the treatment of triple negative breast cancer: a systematic review. Neoplasma 66(6):963\u2013970. https:\/\/doi.org\/10.4149\/neo_2019_190110N34","journal-title":"Neoplasma"},{"key":"6262_CR65","doi-asserted-by":"publisher","DOI":"10.1021\/ja00250a050","author":"H Tanaka","year":"1987","unstructured":"Tanaka H, Kuroda A, Marusawa, et al (1987) Structure of FK 506: a novel immunosuppressant isolated from Streptomyces. J Am Chem Soc. https:\/\/doi.org\/10.1021\/ja00250a050","journal-title":"J Am Chem Soc"},{"issue":"2","key":"6262_CR66","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10143-020-01277-4","volume":"44","author":"IA Tewarie","year":"2021","unstructured":"Tewarie IA, Senders JT, Hulsbergen AFC, Kremer S, Broekman MLD (2021) Beta-blockers and glioma: a systematic review of preclinical studies and clinical results. Neurosurg Rev 44(2):669\u2013677. https:\/\/doi.org\/10.1007\/s10143-020-01277-4","journal-title":"Neurosurg Rev"},{"issue":"24","key":"6262_CR67","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.1158\/1078-0432.CCR-09-2152","volume":"15","author":"S Trompet","year":"2009","unstructured":"Trompet S, De Craen AJM, Mooijaart S, Stott DJ, Ford I, Sattar N, Jukema W, Westendorp RGJ (2009) High innate production capacity of proinflammatory cytokines increases risk for death from cancer: Results of the PROSPER study. Clin Cancer Res 15(24):7744\u20137748","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6262_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pros.24623","volume":"84","author":"A Uleri","year":"2024","unstructured":"Uleri A, Baboudjian M, Tedde A, Rajwa P, Pradere B, Gallioli A, Breda A, Ploussard G (2024) The association between beta-blockers use and prostate cancer mortality: a mini systematic review and meta-analysis. Prostate 84(1):3\u20137. https:\/\/doi.org\/10.1002\/pros.24623","journal-title":"Prostate"},{"issue":"1","key":"6262_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0190619","volume":"13","author":"S Vacher","year":"2018","unstructured":"Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M (2018) High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS ONE 13(1):e0190619. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0190619","journal-title":"PLoS ONE"},{"issue":"9","key":"6262_CR70","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/J.1365-4632.2012.05795.X","volume":"52","author":"N Vercellino","year":"2013","unstructured":"Vercellino N, Romanini MV, Pelegrini M, Rimini A, Occella C, Dalmonte P (2013) The use of propranolol for complicated infantile hemangiomas. Int J Dermatol 52(9):1140\u20131146. https:\/\/doi.org\/10.1111\/J.1365-4632.2012.05795.X","journal-title":"Int J Dermatol"},{"issue":"5","key":"6262_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0010456","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, Thrasivoulou C, Masters JRW, Ahmed A (2010) A novel role for Wnt\/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS ONE 5(5):e10456. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0010456","journal-title":"PLoS ONE"},{"issue":"18","key":"6262_CR72","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.7314\/apjcp.2015.16.18.8031","volume":"16","author":"T Wang","year":"2015","unstructured":"Wang T, Li Y, Lu HL, Meng QW, Cai L, Chen XS (2015) \u03b2-Adrenergic receptors: new target in breast cancer. Asian Pacific J Cancer Prevention: APJCP 16(18):8031\u20138039. https:\/\/doi.org\/10.7314\/apjcp.2015.16.18.8031","journal-title":"Asian Pacific J Cancer Prevention: APJCP"},{"key":"6262_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175135","volume":"929","author":"J Wang","year":"2022","unstructured":"Wang J, Lu S, Meng Y, Fu W, Zhou X (2022) Beta adrenergic blockade and clinical outcomes in patients with colorectal cancer: a systematic review and meta-analysis. Eur J Pharmacol 929:175135. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175135","journal-title":"Eur J Pharmacol"},{"key":"6262_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.CTRV.2016.04.004","volume":"47","author":"J Weberpals","year":"2016","unstructured":"Weberpals J, Jansen L, Carr PR, Hoffmeister M, Brenner H (2016) Beta blockers and cancer prognosis - The role of immortal time bias: a systematic review and meta-analysis. Cancer Treat Rev 47:1\u201311. https:\/\/doi.org\/10.1016\/J.CTRV.2016.04.004","journal-title":"Cancer Treat Rev"},{"key":"6262_CR75","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.301781","author":"S Weiss","year":"2013","unstructured":"Weiss S, Oz S, Benmocha A, Dascal N (2013) Regulation of cardiac L-type Ca2+ channel CaV1.2 via the \u03b2-adrenergic-cAMP-protein kinase A pathway: old dogmas, advances, and new uncertainties. Circulation Res. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.301781","journal-title":"Circulation Res"},{"key":"6262_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.665617","volume":"11","author":"ZY Wen","year":"2021","unstructured":"Wen ZY, Gao S, Gong TT, Jiang YT, Zhang JY, Zhao YH, Wu QJ (2021) Post-diagnostic beta blocker use and prognosis of ovarian cancer: a systematic review and meta-analysis of 11 cohort studies With 20,274 patients. Front Oncol 11:665617. https:\/\/doi.org\/10.3389\/fonc.2021.665617","journal-title":"Front Oncol"},{"issue":"1","key":"6262_CR77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18632\/oncotarget.1083","volume":"5","author":"JK Wolter","year":"2014","unstructured":"Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR, Irwin MS (2014) Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget 5(1):161\u2013172","journal-title":"Oncotarget"},{"key":"6262_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01808-1","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL (2024) Drug repurposing for cancer therapy. Signal Transduction Targeted Ther. https:\/\/doi.org\/10.1038\/s41392-024-01808-1","journal-title":"Signal Transduction Targeted Ther"},{"key":"6262_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109383","author":"X Yan","year":"2022","unstructured":"Yan X, Liu P, Li D, Hu R, Tao M, Zhu S, Wu W, Yang M, Qu X (2022) Novel evidence for the prognostic impact of beta-blockers in solid cancer patients receiving immune checkpoint inhibitors. Int Immunopharmacology. https:\/\/doi.org\/10.1016\/j.intimp.2022.109383","journal-title":"Int Immunopharmacology"},{"issue":"6","key":"6262_CR80","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clbc.2023.05.014","volume":"23","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang S, Jiang W (2023) Impact of beta blockers on breast cancer incidence and prognosis. Clin Breast Cancer 23(6):664-671.e21. https:\/\/doi.org\/10.1016\/j.clbc.2023.05.014","journal-title":"Clin Breast Cancer"},{"key":"6262_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","volume":"121","author":"A Yap","year":"2018","unstructured":"Yap A, Lopez-Olivo MA, Dubowitz J, Pratt G, Hiller J, Gottumukkala V, Sloan E, Riedel B, Schier R (2018) Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth 121:45\u201357. https:\/\/doi.org\/10.1016\/j.bja.2018.03.024","journal-title":"Br J Anaesth"},{"issue":"5","key":"6262_CR82","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","volume":"25","author":"S Zhong","year":"2016","unstructured":"Zhong S, Yu D, Zhang X, Chen X, Yang S, Tang J, Zhao J, Wang S (2016) \u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prevention: off J Eur Cancer Prevention Org (ECP) 25(5):440\u2013448. https:\/\/doi.org\/10.1097\/CEJ.0000000000000192","journal-title":"Eur J Cancer Prevention: off J Eur Cancer Prevention Org (ECP)"},{"issue":"8","key":"6262_CR83","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.4049\/jimmunol.1501677","volume":"196","author":"L Zhou","year":"2016","unstructured":"Zhou L, Li Y, Li X, Chen G, Liang H, Wu Y, Tong J, Ouyang W (2016) Propranolol attenuates surgical stress-induced elevation of the regulatory T cell response in patients undergoing radical mastectomy. J Immunol 196(8):3460\u20133469. https:\/\/doi.org\/10.4049\/jimmunol.1501677","journal-title":"J Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06262-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:18:06Z","timestamp":1757229486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06262-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["6262"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06262-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.A. is the CEO of Oncolodyne, a pre-clinical and clinical stage drug discovery company focused on reprofiling drugs for cancer therapy. This work received no funding from Oncolodyne or any other source, and the company had no involvement in the conception, design, analysis, or writing of this systematic review. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"212"}}